GENENET

Kicking off October, Genenet has been awarded space by Stevenage Bioscience Catalyst (SBC) in its Lab Hotel... There are many pain points in traditional biopharmaceutical research. For example, the high cost of research, time-consuming processes of drug development, and difficulties in treating complicated diseases. These problems not only harm the development of the biopharmaceutical industry, but also generate traumatic problems, such as COVID-19 pandemic, to our world. Genenet Technology provides a one-stop solution to address all these problems, in hope of taking the biopharmaceutical industry to the next level... Our technology offers quick and cost-effective high throughput screening results and this market is expected to exceed USD 20 billion by 2023. We can also help optimizing the production of different products (e.g. enzymes, metabolites, etc.) and this sector exceeded USD 400 billion in 2019.

Also known as: Genenet Limited, Genenet Technology (UK), GENENET TECHNOLOGY LTD

Primary location: London United Kingdom